A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.
Conditions
- EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
- PD-L1 Positive
Interventions
- DRUG: Limertinib+bevacizumab
- DRUG: Limertinib
Sponsor
Shanghai Chest Hospital
Collaborators